The Centrosomal Protein Of 290 kDa pipeline drugs market research report outlays comprehensive information on the Centrosomal Protein Of 290 kDa targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Centrosomal Protein Of 290 kDa pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Ophthalmology which include the indications Leber Congenital Amaurosis (LCA), and Ophthalmology. It also reviews key players involved in Centrosomal Protein Of 290 kDa targeted therapeutics development with respective active and dormant or discontinued products.
The Centrosomal Protein Of 290 kDa pipeline targets constitutes close to five molecules. Out of which, approximately four molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Preclinical, and Discovery stages are 1, 1, 1, and 1 respectively. Similarly, the universities portfolio in Preclinical comprises 1 molecule.
Centrosomal Protein Of 290 kDa overview
Centrosomal Protein of 290 kDa (CEP290) is a large protein that localizes to the centrosome, a crucial cellular organelle involved in microtubule organization and cell division. Mutations in the CEP290 gene have been linked to a spectrum of ciliopathies, which are genetic disorders affecting cilia, hair-like structures protruding from the cell surface with essential roles in various cellular processes. CEP290 plays a pivotal role in ciliary function, where it participates in maintaining the structural integrity of the primary cilium—a microtubule-based organelle protruding from the cell surface. Primary cilia are essential for sensing environmental cues and orchestrating signaling pathways critical for development and tissue homeostasis. One of the well-characterized ciliopathies associated with CEP290 mutations is Leber Congenital Amaurosis (LCA), a severe genetic eye disorder leading to early-onset vision impairment. CEP290 mutations have also been implicated in other ciliopathies such as Joubert syndrome and Senior-Loken syndrome, emphasizing its wide-ranging impact on diverse organs and tissues.
For a complete picture of Centrosomal Protein Of 290 kDa’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
